Atossa Therapeutics Dividend
Atossa Therapeutics declared a dividend of one stapled contingent value right (CVR) for each share of common stock to participate in the potential future monetization of a priority review voucher. The CVRs entitle holders to 25% of the net proceeds from the sale or monetization of the first qualifying FDA priority review voucher awarded to the company, subject to an aggregate payment cap of $50 million. The rights are currently stapled to the common stock and expire on December 31, 2036, if no voucher is awarded.
- Counterparty
- VStock Transfer, LLC
- Term
- through Dec 2036